Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. - Wikidata - awgldk - TriplyDB

Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha.

Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha.

http://www.wikidata.org/entity/Q43520265

about

Hepatitis C Virus, Insulin Resistance, and Steatosis Hepatitis C virus infection and type 1 and type 2 diabetes mellitus Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease Hepatitis C Virus infection in apparentenly healthy individuals with family history of diabetes in Vom, Plateau State Nigeria Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C.Seroprevalence of hepatitis C in type 2 diabetes: evidence for a positive association.Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin.Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy.Risk factors for new onset diabetes mellitus after liver transplantation: A meta-analysis Viruses and diabetes: is there something sweet about hepatitis C infection?Insulin resistance and steatosis in hepatitis C virus infection.Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies.Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B.Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review.Clearance of HCV by Combination Therapy of Pegylated Interferon alpha-2a and Ribavirin Improves Insulin Resistance.Effect of activated vitamin D on glucoparameters in HCV seropositive and seronegative patients on chronic hemodialysis.Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C.The impact of diabetes and obesity on liver histology in patients with hepatitis C.Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association.Regulation of insulin resistance and type II diabetes by hepatitis C virus infection: A driver function of circulating miRNAs.

P2860

Q26751755-6CE406C9-8837-4030-865E-594945FE87D5 Q26829202-3C839990-4217-426A-9AC1-619F7C3FF632 Q27481042-614780E7-1A03-493A-9960-2522639D532D Q27489026-F8460A59-9D4C-451D-94F8-74CCD6DB44C4 Q34099620-94BE0E05-CEF7-4181-A3AD-5EDAD25477B6 Q34351092-A8065B13-4928-4DE5-8367-726487EF986A Q34401965-665E6DE4-5C49-4E0E-B3AD-68D948949975 Q35216879-8B1027F1-D7C2-4480-92B8-FA2EC8A8BF9D Q35649534-67DCF742-0155-48B7-ABCB-3AB3856C0A54 Q36065477-B6E6276D-3D7F-4392-AE0B-D5F8321BC1B7 Q36160709-D097086E-DA37-4E83-A321-FE87BB6AD73B Q36257275-86FB6483-2CCA-4052-A456-057ADF67780A Q37335135-E3ADB8FC-11A0-49C1-B7C2-B8CB81B4DB70 Q37527686-4F0FFFFA-A321-4669-9FD8-F864AC64AAF7 Q37685491-1B09D9E4-8AE7-4351-BAE9-0E21E7D11B08 Q39977681-C62A15E3-27EF-44E5-AE2C-C29ECD4CFDB9 Q42510845-14E60FD6-FF6B-43DE-8739-D91658ECB0ED Q43770083-3C2729E1-B6EA-48A0-B829-069040350B0A Q44393955-211FF42A-21DD-4C58-B561-1FAC23BB5DC6 Q45703319-DE6B2533-C04E-416B-AD05-BAB81E88C8DF Q48091665-60AB14F5-13F2-4D56-856D-1F0605047AFB

P2860

Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha.

http://www.wikidata.org/entity/Q43520265

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

2000年學術文章

@zh

2000年學術文章

@zh-hant

name

Evaluation of factors controll ...... therapy with interferon-alpha.

@en

Evaluation of factors controll ...... therapy with interferon-alpha.

@nl

type

label

Evaluation of factors controll ...... therapy with interferon-alpha.

@en

Evaluation of factors controll ...... therapy with interferon-alpha.

@nl

prefLabel

Evaluation of factors controll ...... therapy with interferon-alpha.

@en

Evaluation of factors controll ...... therapy with interferon-alpha.

@nl

P1433

Q43520265-A5098EE7-6FEB-48EC-B2BE-03E6D09AD951

P1476

Q43520265-6DF62437-D86C-4403-9807-DF10A5E8813D

P2093

Q43520265-14A660AD-E580-4594-9750-26109325BF13

Q43520265-244659ED-96EC-43AC-ADC4-F3163C11B22E

Q43520265-4CBBE230-2717-4F71-A190-84D52505B33A

Q43520265-58E87917-5F4E-4D17-A950-0BDBDBFE1143

Q43520265-58EACF18-1AA8-423A-B3B8-EE1F43F848B5

Q43520265-5C9EE59B-4A95-4E65-83F8-D2C5F6375E35

Q43520265-715236B7-7CAF-4049-8BFF-C526483337FA

Q43520265-9F5B4DE3-CC84-4C3A-A04A-8B8CB742C771

Q43520265-A2537DCF-FB69-455F-8458-1550D2157242

Q43520265-B77F0A14-D3FA-41B0-BB7D-E753BF75CBA3

P2860

Q43520265-020821A3-3F55-453E-89B0-9EB25ED456DB

Q43520265-0539F9E2-A517-4002-AC19-67ADBD83147A

Q43520265-08137D2E-E73C-4FA6-9965-7C6453CBEFAA

Q43520265-1CAEB726-8378-4429-880D-8B790DA54C1B

Q43520265-1D8C5D9A-3C64-4FF4-B855-03A52F8558D9

Q43520265-28F065E9-9AD0-44A6-BEFB-6A837F20BCCD

Q43520265-30EC3182-45C0-4347-9D1B-336A7282FDB7

Q43520265-32380DE4-FD18-4D10-9EA0-59ABBF554CB0

Q43520265-3711295E-3CD2-471B-94EF-AF1E38EB7C95

Q43520265-43F0A342-B265-4E3D-BA8A-5B6C9D8DF580

P304

Q43520265-6055F777-A5FE-4EDF-83D4-0D17C53594F6

P31

Q43520265-B507566C-D0CC-454A-8155-336A6AF93383

P356

Q43520265-F14E5837-C4AA-4B01-9538-74C3558E96B4

P433

Q43520265-0F649719-CC8F-48F3-A4C3-86E1A0AC215C

P478

Q43520265-FC56DB7C-6353-4FC9-ABDD-7CB1E284BFA6

P577

Q43520265-8D08CD82-506B-4553-B049-47A7FB1178F2

P698

Q43520265-9F0C6682-37A5-4CE6-B21C-299A6B94974D

P921

Q43520265-34C33D45-D910-456B-B7BF-962DE0E13800

P356

J.1365-2362.2000.00608.X

P1433

European Journal of Clinical Investigation

P1476

Evaluation of factors controll ...... therapy with interferon-alpha.

@en

P2093

Berger A

http://www.w3.org/2001/XMLSchema#string

Briem D

http://www.w3.org/2001/XMLSchema#string

Cobelli C

http://www.w3.org/2001/XMLSchema#string

Herrmann G

http://www.w3.org/2001/XMLSchema#string

Konrad T

http://www.w3.org/2001/XMLSchema#string

Kusterer K

http://www.w3.org/2001/XMLSchema#string

Lormann J

http://www.w3.org/2001/XMLSchema#string

Teuber G

http://www.w3.org/2001/XMLSchema#string

Toffolo G

http://www.w3.org/2001/XMLSchema#string

Usadel KH

http://www.w3.org/2001/XMLSchema#string

P2860

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

Antidiabetic effects of interleukin 1.

Association of diabetes mellitus and chronic hepatitis C virus infection.

Estimation of beta-cell sensitivity from intravenous glucose tolerance test C-peptide data. Knowledge of the kinetics avoids errors in modeling the secretion.

Disordered energy and protein metabolism in liver disease.

Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose.

Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model.

Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population.

P304

111-121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2362.2000.00608.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2000-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10651835

http://www.w3.org/2001/XMLSchema#string

P921